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Aromatase is a speciﬁc component of the cytochrome P450 enzyme system responsible for the transformation of androgen
precursors into estrogens. This enzyme is encoded by the CYP19A1 gene located at chromosome 15q21.2, that is, expressed in
ovary and testis, but also in many extraglandular sites such as the placenta, brain, adipose tissue, and bone. The activity of
aromatase regulates the concentrations of estrogens with endocrine, paracrine, and autocrine eﬀects on target issues including
bone. Importantly, extraglandular aromatization of circulating androgen precursors is the major source of estrogen in men.
Clinical and experimental evidences clearly indicate that aromatase activity and estrogen production are necessary for longitudinal
bone growth, the attainment of peak bone mass, pubertal growth spurt, epiphyseal closure, and normal bone remodeling in young
individuals. Moreover, with aging, individual diﬀerences in aromatase activity may signiﬁcantly aﬀect bone loss and fracture risk
in men.
1.Background
Sex steroid hormones are important for the acquisition and
maintenance of bone mass in both sexes [1, 2]. Alterations
in their levels can be relevant in the pathogenesis of
osteoporosis and fractures because their deﬁciency may lead
to suboptimal acquisition of peak bone mass in young
individualsorbonelossinadulthood.Whileestrogenseﬀects
in bone in females have been well established (as estrogen
deﬁciency after menopause leads to an imbalance between
bone resorption by osteoclasts and bone formation by
osteoblasts), the role for estrogen in male skeletal health has
only recently become appreciated [3–6]. In fact, even though
alterations in circulating androgen have been associated
with low bone mass and impaired bone strength [7], their
primacy has been increasingly questioned as direct and
indirect evidence has emerged suggesting that estrogens also
play a major role in male skeletal health [3–7]. These new
observations underscore the normal biosynthetic pathway
by which estrogens are made in men, via the activity of
aromatase (a cytochrome P450 product of the CYP19A1
gene) on circulating androgenic precursors (Figure 1).
Of interest, several clinical and experimental studies
on estrogen and/or aromatase deﬁciency also reinforced
the hypothesis of a threshold estradiol level for skeletal
suﬃciency in the male [1–4]. In fact, either in cross-
sectional or longitudinal analysis in aging men bone mineral
density (BMD) and rates of bone loss at diﬀerent skeletal
sites were unrelated to serum estradiol concentrations when
the latter were above the median value, while they were
clearly associated with estradiol at concentrations below the
median [8–10]. This hypothesis gained further support from
a study in which raloxifene (a selective estrogen receptor
modulator) was given to men of varying estradiol levels [11].
Subjects with serum total estradiol levels below 96pmol/liter
responded to raloxifene with a decrease in bone resorption
markers while above this estrogen value, raloxifene caused
an increase in bone resorption markers [11]. Overall, these
observations clearly indicate that men need a suﬃcient
concentration of estrogen, deﬁned as a threshold value,
for normal skeletal remodeling. In all these studies, the
required concentration appeared to be remarkably similar,
ranging from 90 to 110pmol/liter in case of total estradiol
or from 40 to 55pmol/liter in case of bioavailable estradiol
[5]. This apparent threshold value is higher than typical
estradiol concentrations for postmenopausal women who
are not receiving exogenous estrogens. On the other hand,
premenopausal women and young men are typically above2 Journal of Osteoporosis
this apparent threshold level, while up to 50% of middle-
aged men fall below this estradiol threshold and, thus, are
at higher risk of bone loss as shown in several cross-sectional
and longitudinal studies [1–4]. Importantly, estradiol levels
above a given threshold are also important to prevent
fractures, as recently demonstrated in a prospective study of
men from the MrOS cohort [12].
This review summarizes the evidence that aromatase
activity plays an important role in the skeleton in men, either
inyoungindividualsorintheelderly,byitsactionstoconvert
androgens to estrogens in bone and other peripheral tissues.
2. Aromatase andEstrogen Productionin Men
Aromatase is a speciﬁc component of the cytochrome P450
enzyme system that converts the delta 4-3-one A ring of C19
androgen precursors into the corresponding phenolic A ring
characteristic of C18 estrogenic compounds
While in fertile women the ovary represents the major
source of circulating estrogen, which functions as a circu-
lating hormone to act on distal target tissues, in men the
testes account at most for 15% of circulating estrogens,
while the remaining 85% is due to peripheral aromatization
of circulating androgen precursors in diﬀerent tissues [13,
14]. These include the adipose tissue, the brain, the skin,
the endothelium, and the bone. It has been demonstrated
that testicular androgen precursors contribute more to the
total amount of circulating estradiol than adrenal androgens
[15]. In fact, dexamethasone-induced suppression of adrenal
steroid synthesis moderately decreases estradiol concentra-
tions [16], whereas orchidectomy (ORX) leads to a more
dramatic suppression of plasma estradiol [17, 18]. Clearly,
these extragonadal sites of estrogen biosynthesis lack the
ability to synthesize C19 precursors from cholesterol, hence,
their estrogen-producing activity totally depends on the
availability of these circulating C19 androgenic steroids [19].
Moreover, the estrogen synthesized within these extrago-
nadal compartments may be also locally active in a paracrine
or intracrine fashion [13, 20].
In human bone, aromatase is expressed in osteoblast or
osteoblast-like cells from fetal and normal tissue [21–23],
in articular cartilage chondrocytes, in adipocytes adjacent to
bone trabeculae, and in osteocytes, but not in osteoclasts
[23]. Importantly, a recent study demonstrated that aro-
matase gene can be expressed in bone tissue in consistent
amounts, at levels similar to those found in adipose tissue
[24]. In particular, osteoblasts are the major source of
aromatase within the bone microenvironment [24].
Aromatase is encoded by the CYP19A1 gene located at
chromosome 15q21.2 [25]( Figure 2). Despite the presence
of a common CYP19A1 gene, in a tissue-speciﬁc fashion, a
number of untranslated initial exons are found in aromatase
transcripts due to diﬀerential splicing by at least 10 diﬀerent
tissuespeciﬁcpromoters[26–28].Onlythe30-kb3  regionof
the gene (containing exons 2 to 10) encodes aromatase while
al a r g e r9 3 K b5   ﬂanking region serves as the regulatory
unit of the gene [27, 28]. Thus all the multiple exons 1 are
not translated, so that the diﬀerent splicing patterns lead
to transcripts that are all translated as the same protein.
Importantly, this complex structure of the promoter region
ofthegenedeﬁnesthetissue-speciﬁcregulationofaromatase
activity and estrogen biosynthesis. Thus, the ovary, testes,
adipose tissue, brain, and bone each utilize their own
promoters and associated enhancers and suppressors leading
to diﬀerent amounts of mRNA transcripts, mRNA stability
and/or protein translation [26, 29, 30].
In the skeleton, the majority of aromatase transcripts
contain exon 1.4 and exon 1.6 [31–33]. Some minor
transcripts by promoter I.3, PII and If have been also
described [31]. Interestingly, experiments in osteoblast cell
lines demonstrated that cortisol may induce aromatase
gene expression transiently and that 1,25 dihydroxyvitamin
D can maintain its expression, dependent on vitamin D
receptor density [34–36]. Moreover, a more recent study
demonstrated that Runx2 (a key regulator of osteoblast
diﬀerentiation) directly increases aromatase gene expression
in human osteoblast cells by increasing promoter I.4 and I.6
activity [37]. In keeping with this in vitro evidence, a marked
decrease in skeletal aromatase expression has been described
in Runx2-deﬁcient mice [37].
3. AromataseDeﬁciency andthe Male Skeleton
During the past 2 decades, several clinical and experimen-
tal observations underscored the importance of local and
peripheral aromatization of androgens into estrogen for
skeletal homeostasis in males.
3.1. Aromatase Deﬁciency Syndrome. The discovery of
human cases of aromatase deﬁciency preceded the construc-
tion of aromatase knockout animals and, in fact, provided
the ﬁrst insight into the role of estrogens and aromatase in
male skeletal physiology.
Human aromatase deﬁciency is a very rare autosomal
recessive syndrome characterized by congenital estrogen
deprivation caused by loss-of-function mutations in the
CYP19A1 gene [38]. In both genders, the overall severity of
the phenotype may be variable according to residual enzyme
activity [38, 39]. While aﬀected females generally have
ambiguous genitalia at birth and fail to develop secondary
sexual characteristics, the aﬀected male individuals have
normal male sexual diﬀerentiation and pubertal maturation,
and their clinical phenotype mostly develops after puberty
[5, 40]. So far, there are at least 9 known cases of inactivating
mutations in the CYP19A1 gene and aromatase deﬁciency in
men[5,41–49].Allthesepatientsgenerallyshowedmarkedly
low or undetectable estrogen levels while androgens were
normal or even elevated. Interestingly, skeletal maturation
and bone metabolism were severely impaired in all these
subjects, with a similar phenotype to a previously described
male case of loss of function mutation at the estrogen recep-
tor alpha (ESR1)g e n e[ 50]. Common skeletal characteristics
include tall stature and continued longitudinal growth due
to unfused epiphyses, delayed bone age, lack of pubertal
growth spurt, eunuchoid skeletal proportions, genu valgum,
elevated bone resorption markers, and low bone mass.
Moreover, other extraskeletal characteristics, such as lipidJournal of Osteoporosis 3
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Figure 1: Proposed models of sex steroid hormones action on bone.
abnormalities,increasedbodyweight,hyperinsulinemia,and
various degrees of glucose impairment (including diabetes
and acanthosis nigricans in 1 and 2 cases, resp.) have been
also reported in these men.
As in part expected, in 2 of these cases, treatment with
intramuscular testosterone did not give skeletal beneﬁt to
these patients, since aromatase deﬁciency does not lead
to low testosterone levels [5, 47]. Conversely, estrogen
treatment was associated with marked improvements in the
skeletal phenotype. In fact, epiphyses closed quickly, longitu-
dinal growth ceased, and BMD increased consistently at all
assessed skeletal sites [41, 42, 47, 51, 52]. As counterpart,
estrogen replacement in the male case of loss of function
mutation at the ESR1 gene did not improve bone outcomes
[5, 50]. Of interest, consistent with the threshold estradiol
hypothesis for skeletal health, a clear dose-dependent eﬀect
of estrogen replacement therapy on bone mass was evi-
denced, since a very low dose of estradiol (below 25mcg
twice weekly) was not suﬃcient for maintaining a normal
BMD in one of these aromatase-deﬁcient men [52].
In a more recent study, the skeletal phenotype of a 16-
year-old boy with aromatase deﬁciency was investigated by
both DXA and peripheral quantitative computed tomog-
raphy (pQCT) of the radius [46]. The use of the later
technique allowed to assess additional characteristics of
bone strength, such as cross-sectional area (CSA), cortical
thickness, trabecular volumetric BMD, and cortical volu-
metric BMD. Consistent with the previous observations,
estrogen replacement in this boy was associated with the
normalization of sex hormone concentrations, reduced bone
turnover rate, and increases in lumbar spine (+23%) and
femoral neck (+14%) areal BMD. However, the gain in
volumetric BMD (either estimated by the calculation of
the bone mineral apparent density from DXA or assessed
directly by pQCT) was limited at the lumbar spine and
even absent at the femoral neck and the radius. Conversely
longitudinal bone growth, cross-sectional area, and cortical
thickness (as measured by pQCT) increased signiﬁcantly
by 8.5%, 46%, and 12%, respectively. Thus, it was clear
that the observed increase in areal BMD was mainly driven
by an increase in bone size, rather than bone density,
particularly at peripheral sites. Interestingly, these changes
are similar to those associated with normal pubertal growth
and support the notion that in growing bones, except
for the spine true density does not increase [53, 54]. On
the contrary, periosteal diameter continues to expand and
cortical thickness increases during normal male puberty
because of reduced endocortical expansion and accelerated
periosteal apposition [55]. These eﬀects lead to increased
bone size, and have classically been attributed to androgens,
accounting for the greater areal density that is typical of the
male skeleton. In fact, when females enter puberty, periosteal
apposition is inhibited, an action classically believed to be an
estrogen eﬀect. However, according to the eﬀects of estrogen
administration on cross-sectional area and cortical thickness
in this young boy with aromatase deﬁciency [46], some
actions on bone size, previously attributed to androgens,
must at least in part be an estrogen eﬀect. Thus, it is
likely that a biphasic, dose-dependent eﬀect of estrogen at
the periosteum could exist. At low levels (as observed in
males and in early pubertal females) estrogen may stimulate
periosteal apposition and increase bone size, whereas at
higher concentrations (as observed in late pubertal and adult
females) estrogen may inhibit cross-sectional bone growth.
Recently, the concomitant presence of mild hypogo-
nadism in a man with aromatase deﬁciency has oﬀered a
useful model to study the eﬀects of testosterone and estradiol
replacement, separately or in combination [56]. As expected,
in this man, estradiol treatment alone increased BMD with a
greater gain than the one obtained with testosterone alone.
However, the combination of testosterone (6mg/day) and
estrogen (25mcg twice weekly) replacement led to a further4 Journal of Osteoporosis
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Figure 2: Aromatase gene (CYP19A1) with its promoters and untranslated ﬁrst exons. Major polymorphic variants of the CYP19A1 gene
are indicated.
increase in cortical thickness at the radius and the tibia
as measured by pQCT, further supporting the concomitant
importance of both sex steroids for periosteal apposition. In
this case, an increase in volumetric BMD at the tibia and the
radius as well as an increase of areal BMD of the lumbar
spine and the femoral neck was also described after 2 years
of combined therapy.
The skeletal consequences of aromatase deﬁciency have
been illustrated further by studies of the aromatase knock-
out mouse (ArKO) models [57–59]. Overall, these experi-
mental observations generally provided the conﬁrmation of
the human gene disorders suggesting that estrogen may be
more protective in the growing skeleton than androgens in
man, but left open the issues of what, if any, are the roles
of estrogen in regulating bone remodeling and bone loss in
adult males.
3.2. Inhibition of Aromatase Activity: Clinical Studies in
Adult Men. A ﬁrst indirect indication about the importance
of aromatase and the relative roles of estrogen versus
testosterone in the adult male skeleton came from cross-
sectional and longitudinal observations in middle-aged and
elderly men. In fact, in most of these studies BMD and bone
loss were more directly related to declining estrogen levels
thandecliningandrogenlevels,particularly,whencirculating
bioavailable fractions of these steroids were considered [8–
10, 60–66]. Moreover, in one of these studies, the ratio
between estradiol and testosterone presumed to be an indi-
rect index of aromatase activity, increased signiﬁcantly with
age, and was higher in normal than in osteoporotic subjects
or in men with fragility fractures [10]. Consistent with these
ﬁndings, other clinical evidences underlined the importance
ofestrogenontheadultmaleskeleton.Thus,inapreliminary
observation, Taxel and Raisz described signiﬁcant reductions
in bone resorption markers in 9 elderly men treated short
term with either 0.5mg or 2.0mg daily of micronized 17β-
estradiol [67]. In a diﬀerent study, Anderson et al. treated 21
eugonadalosteoporoticmenwithintramusculartestosterone
andfoundasigniﬁcantincreaseinlumbarspineBMD,which
was correlated with changes in serum estradiol, but not
circulating testosterone [68].
In order to deﬁnitively dissect out estrogen versus
testosterone eﬀects on the adult male skeleton, more
dynamic short-term interventional observations have been
performed,wherearomataseactivitywassuppressedthrough
the use of aromatase inhibitors. In a ﬁrst study, Falahati-Nini
et al. [69] examined the diﬀerential eﬀects of estrogen versus
testosterone replacement in a group of 59 elderly men (mean
age 68 yr) following the induction of hypogonadism (by the
use of a GnRH agonist, Lupron) and aromatase inhibition
(withletrozole2.5mgdaily).Ofinterest,theincreaseinbone
resorption markers (deoxypyridinoline and N-telopeptide of
type I collagen) associated with the use of the GnRH agonist
was almost completely prevented by estradiol but not by
testosterone therapy alone, indicating that the increase in
bone resorption was due primarily to estrogen loss, not to
testosterone loss. In the case of bone formation markers,
there was evidence for stimulatory eﬀects of both estrogen
and testosterone on serum osteocalcin but not the amino-
terminal propeptide of type I procollagen that only increased
with estrogen replacement. Since osteocalcin is produced
primarily by mature osteoblastic cells and osteocytes [70],
these ﬁndings are consistent with an important role for
both estrogen and testosterone in maintaining the functional
integrity of these cells. Type I collagen, by contrast, is
produced by cells of the entire osteoblastic lineage [71],
and these data would suggest that it is primarily estrogen
that regulates osteoblast diﬀerentiation. These results were
in part replaced in a similar study performed in younger
individuals, [72] following the induction of the hypogonadal
state by the GnRH agonist, goserelin acetate. In this model,
evidencewasprovidedforindependenteﬀectsoftestosterone
a n de s t r o g e no nb o n er e s o r p t i o n .As u b s e q u e n ts t u d yb y
Taxel et al. [73] with a longer observation period (9 weeks)
also gave similar results, further indicating that treatment
of elderly men with an aromatase inhibitor (in this speciﬁc-
case anastrozole 2mg/day) produces signiﬁcant increases in
bone resorption and decreases in bone formation. These
eﬀectsonboneturnovermaybelessevidentwithlowerdoses
(i.e., anastrozole 1mg/day or less), or in case of borderline
hypogonadism (testosterone levels less than 350ng/dl), at
least over a short-term period of treatment [74]. To this
regard, a more recent study assessed the 12 months eﬀects
of a low dose of anastrozole (1.0mg/day) on BMD and bone
turnover markers in 69 men (aged 60 yr or older) with
low or low-normal testosterone levels [75, 76]. Interestingly,
with this longer observation period, despite an increase in
testosterone levels at all time points, a statistically signiﬁcant
decreaseinposterior-anterior spine BMDversusplacebo was
described, likely due to the parallel mild decrease in serumJournal of Osteoporosis 5
estradiol. Qualitatively similar changes, although nonsignif-
icant, were observed at the other bone sites. Conversely,
bone turnover markers were not signiﬁcantly aﬀected by
aromatase inhibition, in this study.
4. VariationinAromataseActivityand
Bone MetabolisminMen
All the above clinical and experimental models (in which
aromatase activity is absent or inhibited) have clearly shown
that aromatase and estrogen production are important
factors in male skeletal health. These models, however, were
mainly based on conditions of complete estrogen deﬁciency,
while they did not address the potential skeletal implications
of interindividual variation in aromatase eﬃciency [5, 14].
Such diﬀerences in aromatase activity, and, hence, estrogen
levels, might become particularly important in elderly males
in whom age-related declines in testicular and adrenal
androgen precursors are common.
4.1. Inherited Variation in Aromatase Activity. Several poly-
morphic regions have been detected in the human CYP19A1
gene that could be responsible for qualitative and/or quan-
titative diﬀerences in gene expression and aromatase activity
(Figure 2).Themostwidelystudiedincludeasilentpolymor-
phism (G/A at Val80) in exon 3, a tetranucleotide (TTTA)n
tandem repeat polymorphism in intron 4, a Arg264Cys
(C/T) substitution in exon 7, and a single nucleotide change
(C/T) in exon 10. These polymorphisms were investigated
in postmenopausal women or elderly men. In particular,
several studies evidenced an association between the number
of TTTA repeats and estrogen levels, breast cancer, or
osteoporotic risk [77–83]. More recently other polymorphic
variants within the promoter region of the CYP19A1 gene
have been widely investigated and associated with BMD
in both genders as well as with susceptibility to breast or
uterine cancer in females [84–86]. Most of these evidences
were conﬁrmed in subsequent meta-analyses and large scale
studies [87–91]. Thus, it is possible that the presence of
particular CYP19A1 variants could be responsible of higher
aromatase activity and increased estrogen production. If so,
these polymorphisms should be protective for bone loss in
elderlymenorpostmenopausalwomenwhilepotentiallyalso
increasing the risk of estrogen-related cancer.
Of interest, the skeletal consequences of genetic variation
in CYP19A1 appear to be modulated by fat mass, particularly
in men. In fact, BMD diﬀerences associated with CYP19A1
genotypes were greater in male subjects with a normal
BMI, while the association progressively decreased when
overweight and obese men were analyzed [81]( Figure 3).
This point suggests that fat mass may be a mitigating
factor in the expression of CYP19A1 genotypes on bone.
It is possible that with more adipose tissue, the associated
increase in adipose aromatase activity dominates any eﬀect
of the polymorphisms on intrinsic aromatase activity.
Given the importance of estrogen in bone growth, it is
likely that genetic variation in CYP19A1 may be also relevant
for young individuals, before the attainment of peak bone
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Figure 3: Lumbar BMD values according to CYP19A1 (TTTA)n
repeat genotype in subjects divided by BMI in normal (BMI ≤ 25)
and overweight or obese groups (BMI > 25), respectively. Subjects
were grouped according to short (S, TTTA ≤ 9) and long (L, TTTA
> 9) repeats number (adapted from [81]).
mass. Despite an initial study in 140 middle-aged Finnish
men evidenced an association between the number of TTTA
repeat sequences and height or BMI but not with BMD
[92], a larger analysis in younger individuals conﬁrmed that
CYP19A1 polymorphisms signiﬁcantly aﬀect the attainment
of peak bone mass [93]. Thus, in a well-characterized cohort
of 1068 men at the age of peak bone mass (18.9 ± 0.6
years), both the TTTA repeat variation and a silent G/A
polymorphismatVal80oftheCYP19A1genewerepredictors
ofarealBMD,lumbarspine,totalbody,andcorticalbonesize
(cortical cross-sectional area and thickness) at 2 peripheral
sites (radius and tibia).
To date, the molecular mechanisms through which the
diﬀerent CYP19A1 variants aﬀect aromatase activity, and
bone metabolism remain in great part unknown. In a
preliminary analysis, higher in vitro aromatase eﬃciency
and greater estrogen production were observed in ﬁbroblasts
from men with a high TTTA repeat genotype than in men
bearing a low TTTA repeat genotype [81]. Even though,
it is unlikely that this polymorphism might have a direct
eﬀect on aromatase expression and activity (due to its
introniclocationwithintheCYP19A1gene),adiﬀerentstudy
described a strong degree of linkage disequilibrium between
the TTTA repeat variation and the C-T substitution in exon
10, just 19 base-pairs downstream of the termination site
of translation [78]. Interestingly, in that study, the T allele
was associated with a higher number of TTTA repeats and
showed a high-activity phenotype, with increased aromatase
activity, increased aromatase mRNA levels, and with a
switch in promoter usage from adipose tissue promoter
to the more active ovary promoter. More recent studies
also evidenced a functional role of other polymorphisms
located within the complex promoter region of the CYP19A1
gene. In particular, a C/G polymorphisms in promoter6 Journal of Osteoporosis
I.2 (rs1062033) were associated with diﬀerences in gene
transcription by interacting with the transcription factor
CEBPβ [94], which aﬀects aromatase expression in diﬀerent
tissues [95, 96]. In fact, the expression of the reporter
luciferase gene in osteoblast cell lines was signiﬁcantly higher
in constructs bearing the G allele (which was also associated
with higher BMD in population studies) than in those with
the C allele, and this diﬀerence was particularly evident after
cotransfection with CEBPβ. Consistent with these results,
diﬀerential allelic expression was also evidenced in bone
tissue samples, again indicating the G allele as the more
overexpressed. Although these studies, in the aggregate,
provide data to argue for the importance of CYP19A1
polymorphisms as determinants of estrogen production and
bone strength, larger and more deﬁnitive studies are needed
before any ﬁrm conclusion can be drawn.
Interestingly, epigenetic eﬀects on aromatase transcrip-
tion and activity have been also evidenced in recent
studies. In fact, CpG methylation has been described as
an important epigenetic mechanism for the regulation of
CYP19A1 expression. To this regard, an in vitro study
performed in skin ﬁbroblast indicated that diﬀerences in
methylation patterns may be responsible for the observed
interindividual variation in promoter-driven expression of
aromatase [97]. In particular, in this study, unmethylated
constructsshowedconsistentlyhigherpromoteractivitythan
methylated constructs.
4.2. Acquired Variation in Aromatase Activity. Besides the
above genetic and epigenetic considerations, several addi-
tional mechanisms have been proposed in which aromatase
activity could be modulated under certain circumstances in
diﬀerent tissues. It is known, for example, that aromatase is a
speciﬁc marker of the undiﬀerentiated adipose mesenchymal
cellphenotypewhileitislessexpressedinmatureadipocytes.
Thus, factors that stimulate adipocyte diﬀerentiation, such
as PPARγ agonists could also lead to the downregulation of
aromatase gene and a reduction in aromatase activity [98–
100]. Of course, if there are more adipocytes, there could
be more aromatase activity even with reduced production
of estrogen per fat cell. Moreover, the skeletal eﬀects of
PPARγ agonists are more complex and mainly involve direct
negative eﬀects on bone cells [101]. Other agents acting
on PPARγ and PPARα pathways, such as the phthalates
(ubiquitous environmental toxins found in plasticizers) have
beenassociatedwithadecreaseinaromatasemRNAandaro-
matase activity in ovarian granulosa cells [102]. Moreover,
the activation of PPARα pathway by fenoﬁbrate in female
micesigniﬁcantlyreducedaromatasemRNAandactivityand
was associated with a decrease in femoral BMD and uterine
size [103]. Despite these diﬀerent experimental evidences,
theclinicalrelevanceoftheseenvironmentalagentsonglobal
aromatase activity and estrogen production in man remains
unknown.
Several other contaminants may aﬀect aromatase activity
and estrogen production. Glyphosate-based herbicides are
toxic and endocrine disruptors in human cell lines that are
widely used across the world. Their residues are frequent
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pollutants in the environment and are spread on most eaten
transgenic plants, modiﬁed to tolerate high levels of these
compounds in their cells. While up to 400ppm of these
residuesareacceptedinsomefeed,recentexperimentalstud-
ies demonstrated that aromatase transcription and activity
were disrupted with subagricultural doses and with residues
from 10ppm [105]. In addition, a diﬀerent study indicated
that phytochemicals such as procyanidin B dimers contained
in red wine and grape seeds inhibits aromatase activity
in vitro and suppress aromatase-mediated breast tumor
formation in vivo [106]. To this regard, it has been assumed
that daily consumption of 125mL of red wine would provide
adequate amounts of procyanidin B dimers to suppress in
situ aromatase in an average postmenopausal woman. By a
diﬀerent mechanism myosmine, a minor tobacco alkaloid
widely occurring in food products of plant and animal
origin inhibits the conversion of testosterone to estradiol
by human aromatase with potential implications for sex
hormone homoeostasis [107]. Another important and well-
recognized modulator of aromatase eﬃciency in bone cells is
vitamin D that has been shown to stimulate glucocorticoid-
induced aromatase activity in cultured osteoblasts [35]. The
magnitude of this eﬀect varies largely among individuals,
depending on the level of the vitamin D receptor [107]. Of
interest, vitamin D receptor knock-out mice showed reduced
aromatase activity with respect to wild-type animals [108].
Importantly aromatase activity may be also aﬀected
by pathological conditions. In this respect, it is known
that increased androgen aromatization can occur in case
of hepatocellular carcinoma [109], adrenocortical tumors
[110],andtesticulartumors[111,112].Inalltheseneoplastic
conditions, inappropriate amounts of aromatase enzyme
are expressed and estrogen levels are increased. Elevated
plasma estradiol concentrations also have been described
in men with liver cirrhosis together with decreased plasma
testosterone [112, 113]. In these patients, the metabolic
clearance rate of estrogens seems to be unaltered, suggesting
that the observed hyperestrogenism could be caused solely
by an increase in aromatization of androgen precursors.
Conversely, other pathological conditions may negatively
aﬀect aromatase activity and estrogen levels in males. In a
preliminary study on elderly men Figura et al. describedJournal of Osteoporosis 7
signiﬁcant diﬀerences in estradiol levels in relation to Heli-
cobacter pylori infection, independently from circulating
testosterone levels [105]. Serum concentrations of estradiol
were signiﬁcantly lower in infected CagA-positive patients
than CagA-negative patients (Figure 4), and this variation
was associated with diﬀerences in bone turnover. The
mechanism underlying this association is unknown and
deserves further investigations. Indeed, aromatase activity
and production of estradiol were recently demonstrated in
gastric parietal cells [114]. Finally, more recent observations
suggestedthatdiabetesmaynegativelyaﬀectexpressionlevels
of aromatase at least in the ovary and the testis [115,
116]. The eﬀects of this disorder on major extragonadal
sites of aromatase activity including bone remains to be
determined. Of interest, experimental studies also evidenced
that oral antidiabetic agents such as metformin can decrease
aromatase expression in both granulose-luteal cells and
breast adipose cells while, on the opposite, insulin has been
associated with enhanced aromatase expression in diﬀerent
cell lines [117, 118]. Importantly, since a recent study
evidenced that metformin-induced inhibition of aromatase
expression occurs via the downregulation of promoter II,
I.3, and 1.4 [118], its potential negative eﬀects on skeletal
estrogen production and bone health should be investigated.
5. Conclusions
Extraglandular aromatization of circulating androgen pre-
cursors is the major source of estrogen in men. Several
lines of clinical and experimental evidence now clearly
indicate that aromatase activity and estrogen production are
necessary in men (as well as in women) for longitudinal
bone growth, the pubertal growth spurt, epiphyseal closure,
normal bone remodeling, and the attainment of peak bone
mass. Moreover, like in women, estrogen production from
androgen precursors by peripheral aromatase activity (even
within the bone) is also important for the maintenance of
bonemassandthepreventionofbonelossinagingmen.Fur-
ther studies are required to better understand how genetic,
epigenetic, environmental, pathologic, and pharmacological
inﬂuences might modulate aromatase activity, increasing or
reducing estrogen production in ageing individuals, and
thereby aﬀecting skeletal health.
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